A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04971729 in Lean To Obese, Otherwise Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 14 Apr 2015 Protocol has been amended to change in primary endpoints and treatment arms.
- 08 Jul 2010 Actual number of patients added to 12 as reported by ClinicalTrials.gov.
- 29 Jun 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.